Neuroimaging biomarkers define neurophysiological subtypes with distinct trajectories in schizophrenia

Yuchao Jiang,Jijun Wang,Enpeng Zhou,Lena Palaniyappan,Cheng Luo,Gongjun Ji,Jie Yang,Yingchan Wang,Yuyanan Zhang,Chu-Chung Huang,Shih-Jen Tsai,Xiao Chang,Chao Xie,Wei Zhang,Jinchao Lv,Di Chen,Chun Shen,Xinran Wu,Bei Zhang,Nanyu Kuang,Yun-Jun Sun,Jujiao Kang,Jie Zhang,Huan Huang,Hui He,Mingjun Duan,Yingying Tang,Tianhong Zhang,Chunbo Li,Xin Yu,Tianmei Si,Weihua Yue,Zhening Liu,Long-Biao Cui,Kai Wang,Jingliang Cheng,Ching-Po Lin,Dezhong Yao,Wei Cheng,Jianfeng Feng,the ZIB Consortium

DOI: https://doi.org/10.1038/s44220-023-00024-0

2023-03-23

Nature Mental Health

Abstract:Technical developments and improved access to neuroimaging techniques have brought us closer to understanding the neuropathological origins of schizophrenia. Using data-driven disease-progression modelling on cross-sectional magnetic resonance imaging (MRI) from 1,124 patients with schizophrenia, we characterize two distinct but stable 'trajectories' of brain atrophy, separately beginning in the Broca's area (subtype1) and the hippocampus (subtype2). The two trajectories are replicated in cross-validation samples. Individuals within each subtype are further classified into two stages ('pre-atrophy' and 'post-atrophy'). These subtypes show different atrophy patterns and symptom profiles. Longitudinal data from 523 patients with schizophrenia treated by antipsychotics only or adjunct transcranial magnetic stimulation (TMS) reveal that antipsychotics-only effects relate to phenotypic subtype (more effective in the subtype1) while adjunct transcranial-magnetic-stimulation effects relate to the stage (superior outcomes in the pre-atrophy stage). These findings suggest distinct pathophysiological processes underlying schizophrenia that potentially yield to stratification and prognostication—a key requirement for personalizing treatments in enduring illnesses.